SCHEMBL7073444

SCHEMBL7073444

COC(=O)Cc1cc2ccc(OCCNC(=O)OC(C)(C)C)cc2[nH]c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.51
HSD17B10 Q99714 10/20 0.51
ALDH1A1 P00352 8/20 0.51
TSHR P16473 5/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 4/20 0.47
TP53 P04637 1/20 0.47
ALOX15 P16050 1/20 0.47
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
CYP1A2 P05177 1/20 0.45
HPGD P15428 4/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PDK2 Q15119 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
KMT2A Q03164 2/20 0.42
GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7072011 0.97 KDM4E (0.50) KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2
SCHEMBL7075216 0.94 KDM4E (0.49) KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2
SCHEMBL7071729 0.90 HSD17B10 (0.54) KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2
SCHEMBL27581914 0.86 KDM4E (0.46) KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2
SCHEMBL7127467 0.84 KDM4E (0.48) KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2
SCHEMBL7071727 0.83 CA12 (0.45) KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2
SCHEMBL7075764 0.81 HSD17B10 (0.48) KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2
Trifluoroacetic Acid SCHEMBL7072029 0.81 HSD17B10 (0.46) KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2
SCHEMBL27561574 0.80 CA12 (0.47) KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2
Trifluoroacetic Acid SCHEMBL7073292 0.79 KDM4E (0.45) KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin WYETH (US) 2003-06-12 US disclosed
US-6429214-B1 INHIBITORS OF BONE RESORPTION WYETH 2002-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin ITGAV, ITGB2, ITGB3 KDM4E 560/4885HSD17B10 3835/4885ALDH1A1 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.